FibroGen Inc. (NASDAQ:FGEN) shares traded 11.80% higher at $18.00 on Wall Street last session.
In accordance with the data, 7 analysts cover FibroGen Inc. (NASDAQ:FGEN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $27.00 and a low of $9.00, we find $15.00. Given the previous closing price of $16.10, this indicates a potential downside of -6.83 percent. FGEN stock price is now 16.63% away from the 50-day moving average and 40.11% away from the 200-day moving average. The market capitalization of the company currently stands at $1.66B.
It has been rated a hold by 5 analysts and a buy by 1. Brokers who have rated the stock have averaged $17.60 as their price target over the next twelve months.
With the price target enhanced from $18 to $27, BofA Securities Upgraded its rating from Neutral to Buy for FibroGen Inc. (NASDAQ: FGEN). On September 22, 2021, Goldman Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock reducing its target price from $16 to quote $11, while ‘Raymond James’ rates the stock as ‘Mkt Perform’.
In other news, Wettig Thane, Chief Commercial Officer sold 734 shares of the company’s stock on Dec 23. The stock was sold for $11,597 at an average price of $15.80. Upon completion of the transaction, the Chief Commercial Officer now directly owns 89,163 shares in the company, valued at $1.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 12, Chief Financial Officer Graham Juan sold 1,407 shares of the business’s stock. A total of $20,402 was realized by selling the stock at an average price of $14.50. This leaves the insider owning 53,703 shares of the company worth $0.97 million. Insiders disposed of 62,138 shares of company stock worth roughly $1.12 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FGEN stock. A new stake in FibroGen Inc. shares was purchased by ADAGE CAPITAL PARTNERS GP, L.L.C. during the first quarter worth $49,500,000. MARSHALL WACE, LLP invested $13,680,000 in shares of FGEN during the first quarter. In the first quarter, EAGLE ASSET MANAGEMENT INC acquired a new stake in FibroGen Inc. valued at approximately $13,295,000. MASSACHUSETTS FINANCIAL SERVICES CO /MA/ acquired a new stake in FGEN for approximately $1,545,000. TRI LOCUM PARTNERS LP purchased a new stake in FGEN valued at around $1,338,000 in the second quarter. In total, there are 236 active investors with 78.70% ownership of the company’s stock.
FibroGen Inc. (NASDAQ: FGEN) opened at $16.70 on Thursday. During the past 12 months, FibroGen Inc. has had a low of $7.81 and a high of $18.31. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.90, and a quick ratio of 1.70. The fifty day moving average price for FGEN is $15.43 and a two-hundred day moving average price translates $12.85 for the stock.
The latest earnings results from FibroGen Inc. (NASDAQ: FGEN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.78, beating analysts’ expectations of -$0.94 by 0.16. This compares to $0.54 EPS in the same period last year. The company reported revenue of $15.73 million for the quarter, compared to $155.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -89.91 percent. For the current quarter, analysts expect FGEN to generate $31.59M in revenue.
FibroGen Inc.(FGEN) Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.